Compare CETY & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CETY | RNAZ |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 8.5M |
| IPO Year | 2020 | 2021 |
| Metric | CETY | RNAZ |
|---|---|---|
| Price | $0.86 | $8.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $280.00 |
| AVG Volume (30 Days) | ★ 1.1M | 8.7K |
| Earning Date | 04-13-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.50 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $957,633.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.18 | $0.22 |
| 52 Week High | $3.05 | $20.99 |
| Indicator | CETY | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 51.06 | 41.78 |
| Support Level | $0.82 | $8.47 |
| Resistance Level | $1.04 | $9.70 |
| Average True Range (ATR) | 0.09 | 0.66 |
| MACD | -0.00 | -0.10 |
| Stochastic Oscillator | 33.01 | 4.02 |
Clean Energy Technologies Inc is clean energy and environmentally sustainable technologies company offering heat recovery solutions products. In addition, it also provides engineering and manufacturing solutions focused on other energy-efficient and environmentally sustainable technologies. The company's principal product is the Clean Cycle generator, offered by Heat Recovery Solutions. The company's engineering and manufacturing resources support its heat recovery solutions business. It has four segments: Clean Energy HRS & CETY Europe, CETY Renewables Waste to Energy Solutions, Engineering and Manufacturing Business and CETY HK. It serves various markets, including industrial, aerospace, military, instrumentation, and medical.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.